Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.49 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29483989 | 1.00 | KMO (0.55) | KMOPKMIRAK4PIK3CAKDM4E | |
| Hydrochloric Acid SCHEMBL22234574 | 0.98 | KMO (0.54) | KMOPKMIRAK4PIK3CAKDM4E | |
| SCHEMBL2815393 | 0.87 | IRAK4 (0.60) | KMOPKMIRAK4PIK3CAKDM4E | |
| SCHEMBL12734079 | 0.86 | IRAK4 (0.53) | KMOPKMIRAK4PIK3CAKDM4E | |
| SCHEMBL836939 | 0.85 | GNE (0.60) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL14879835 | 0.85 | GNE (0.56) | KDM4EALOX15TSHRACMSDTDP1 | |
| Hydrochloric Acid SCHEMBL26695120 | 0.84 | IRAK4 (0.52) | KMOPKMIRAK4PIK3CAKDM4E | |
| SCHEMBL31432279 | 0.83 | HSD11B1 (0.61) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL1781915 | 0.83 | HSD11B1 (0.61) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL22849533 | 0.82 | IRAK4 (0.53) | PKMIRAK4PIK3CAKDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310356-B1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | claimed |
| JP-2011529057-A | — | — | 2011-12-01 | — | — | JP | claimed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | claimed |
| WO-2010011570-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | WO | claimed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | claimed |
| US-20060223996-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-05 | — | — | US | claimed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12441736-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| CN-119409684-A | Five-membered and six-membered compound, preparation method, pharmaceutical composition and application | 杭州多域生物技术有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-118076596-B | Five-membered and six-membered compound, preparation method, pharmaceutical composition and application | 杭州多域生物技术有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-3898592-B1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | AMGEN INC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| CN-118076596-A | Five-membered and six-membered compound, preparation method, pharmaceutical composition and application | 杭州多域生物技术有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2010056549-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| WO-2010011570-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
| EP-1819341-A2 | IL-12 MODULATORY COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20060223996-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-05 | — | — | US | disclosed |
| WO-2006053227-A2 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223996-A1 | IL-12 modulatory compounds | IL2, IL4, IFNG | KMO 1707/4885PKM 3729/4885IRAK4 55/4885 |
| US-12441736-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | KMO 2074/4885PKM 575/4885IRAK4 3131/4885 |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, ADM2, PDE3B | KMO 4236/4885PKM 3889/4885IRAK4 3126/4885 |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | KMO 3233/4885PKM 575/4885IRAK4 248/4885 |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | KMO 1707/4885PKM 3729/4885IRAK4 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.